Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(6)
•••
Post by EbbFlow88on Aug 19, 2021 8:41am
152 Views
Post# 33729320

New Globe Article

New Globe Article https://www.theglobeandmail.com/business/article-for-knight-therapeutics-founder-and-ceo-jonathan-goodman-handing-the/

Samira is just getting started. Lots to prove with Goodman there to offer guidance. 


The incoming CEO is optimistic Knight can grow its profits despite obstacles. Drugs such as Exelon, a dementia fighter whose rights Knight recently purchased for Canada and Latin America, have staying power, she says. And as Knight works through the Biotoscana acquisition, she says the company will beef up its disclosure – something that should get investors more comfortable about its prospects.

“I know that there’s a lot of fear of the next levels of COVID, but we are going to come out of it,” Ms. Sakhia says. “We’re already talking about return to office. We’re talking about return for the [sales] reps. The world is going to wake up again. And we want to be ready.”
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities